Yeduc 15mg (Sibutramina)
What is Yeduc 15mg (Sibutramina) ?
Yeduc 15mg (Sibutramina) is a slimming drug based on the active substance sibutramine. Its active ingredient is sibutramine. yeduc acts as an appetite suppressant, an enhancer of satiety.
Yeduc 15mg (Sibutramina) blocks nerve cells that release and reabsorb serotonin. This implies an increase in serotonin levels. This increase acts in the brain, makes it believe that the stomach is full and increases the sensations of fullness so that you eat less and end up losing weight. Reductil should be taken in addition to a low-calorie (but balanced) diet.
How Yeduc 15mg works ?
Doing more physical exercise on a regular basis is also recommended. One study showed that while sibutramine is taken in combination with a low-calorie diet and a regular exercise routine, 77% of patients managed to lose weight and improve their health (thanks to this weight loss).
There are 3 dosages: 10 mg, 15 mg and 20 mg. You have to take 1 pill of Yeduc each morning. This slimming medication can be taken with or without food. The duration of treatment with sibutramine should not exceed 12 months (a duration of 6 months is recommended).
In placebo-controlled studies, 9% of those treated with sibutramine, 7% of those who received placebo, dropped out of the study due to adverse effects.
The most common effects were: Headache, back pain, flu syndrome, accident damage, asthenia, abdominal pain; tachycardia and vasodilation, hypertension / increase in blood pressure, palpitation; anorexia, constipation, paradoxical increase in appetite, nausea, dyspepsia; arthralgia; dry mouth, insomnia, nervousness, anxiety, depression, rhinitis, pharyngitis, sinusitis and rash.
Other uncommon effects were: chest pain, neck pain, allergic reactions, rectal disorders; myalgia, tenosynovitis, joint disorders; paresthesias, somnolence, CNS stimulation, emotional lability; sweating; taste alteration, hearing disorders and ear pain; and dysmenorrhea.
Co-administration with ketoconazole (and erythromycin, to a lesser degree) may decrease the metabolism of sibutramine. Sibutramine should not be administered if the patient is being treated with other drugs that act on the central nervous system, in particular with serotonergic drugs (for example: fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine) alone or in combination with MAOIs (phenelzine, selegiline), There have been reports of serious reactions, sometimes fatal. Serotonin syndrome, which has also been reported with the use of selective serotonin reuptake inhibitors (sumatriptan) and anti-migraine drugs (dihydroergotamine) and certain opioids (dextromethorphan, meperidine, pentazocine, fentanyl), lithium and tryptophan. The syndrome includes: excitement, hypomania, restlessness, confusion, disorientation, anxiety, agitation, motor weakness, myoclonus, tremor, hemiballism, hyperreflexia, ataxia, dysarthria, incoordination, hyperthermia, chills, mydriasis, diaphoresis, emesis, tachycardia, unconsciousness. It requires immediate attention.